Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6IU/kg/week sc, six times a week for 12 months) were evaluated in 12 girls (chronological age 9.4 +/- 1.6 years) suffering from central precocious puberty with growth velocity less than 4 cm/year and no substantial increase or decrease in predicted adult height during gonadotropin releasing hormone (Gn-RH) analogue treatment(D-Trp(6)-LH-RH, 60 mu g/kg im/28 days). At baseline, large variations were observed in nocturnal growth hormone (GH) means (pathological values (< 3.6 mu g/l) 33.3%), stimulated levodopa GH peaks (pathological values (<10.0 mu g/l) 28.6%) and serum insulin-like growth factor-I (IGF-I) levels. Neither GH nor IGF-I levels were correlated with growth velocity. During recombinant GH therapy, growth velocity increased significantly (baseline 3.0 +/- 0.9 cm/year; 6 months 6.4 +/- 1.9 cm/year, p < 0.001 versus baseline; 12 months 6.0 +/- 1.3 cm/year, p < 0.001 versus baseline). There was a significant increase in height SDS for bone age (baseline -1.6 +/- 0.5 SDS; 12 months -1.04 +/- 0.6 SDS; p < 0.002) and in predicted adult height (baseline 152.0 +/- 3.6 cm; 12 months 155.9 +/- 3.4 cm; p < 0.002). Our results suggest that combined therapy with Gn-RH analogues and recombinant GH can improve growth velocity and predicted adult height in girls with central precocious puberty and impaired height prognosis during Gn-RH analogue treatment.
|Autori interni:||SAGGESE, GIUSEPPE|
|Autori:||SAGGESE G; PASQUINO AM; BERTELLONI S; BARONCELLI GI; BATTINI R; PUCARELLI I; SEGNI M; FRANCHI G|
|Titolo:||Effect of combined treatment with gonadotropin-releasing-hormone analog and growth-hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis|
|Anno del prodotto:||1995|
|Digital Object Identifier (DOI):||10.1111/j.1651-2227.1995.tb13632.x|
|Appare nelle tipologie:||1.1 Articolo in rivista|